Innovaderm Research Inc., Montreal, Quebec, Canada.
J Eur Acad Dermatol Venereol. 2023 Jun;37(6):1168-1174. doi: 10.1111/jdv.18925. Epub 2023 Feb 13.
Tapinarof is a topical, aryl-hydrocarbon receptor agonist that has recently received FDA-approval for the treatment of psoriasis. This novel therapeutic has also been shown to be effective for atopic dermatitis and is currently in phase 3 for this indication. Beyond good efficacy and fast onset of action in patients with psoriasis, the clinical response to tapinarof is notable for durable remission or near remission, maintained for an average of 130 days beyond treatment discontinuation in patients with psoriasis in phase 3 studies. Tapinarof is usually well tolerated but can induce a follicular inflammatory reaction and dermatitis in some patients. This narrative review covers the historical development of this molecule, safety and efficacy data from clinical trials conducted with various topical formulations, and practical considerations derived from our 15 years of clinical trial experience with the drug.
他卡西醇是一种新型外用制剂，有报道其治疗斑块状银屑病的疗效确切，且不良反应轻微。他卡西醇是维生素 D 衍生物，作用于皮肤角质形成细胞，诱导其分化，抑制其增生，从而发挥治疗作用。我们就其作用机制、药代动力学、临床疗效、不良反应和应用注意事项进行综述。
